Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 3, 2016, Pages 704-709

  Weissmann, Marina ^a   Arvatz, Gil ^a   Horowitz, Netanel ^b   Feld, Sari ^a   Naroditsky, Inna ^b   Zhang, Yi ^c   Ng, Mary ^c   Hammond, Edward ^d   Nevo, Eviatar ^e   Vlodavsky, Israel ^a   Ilan, Neta ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Rambam Health Care Campus ^*  (Israel)

^c ELI LILLY AND COMPANY   (United States)

^d Progen Pharmaceuticals Limited   (Australia)

^e UNIVERSITY OF HAIFA   (Israel)

Author keywords

Heparanase; Lymphoma; Metastasis; Neutralizing antibody; Tumor growth

Indexed keywords

ANTINEOPLASTIC AGENT; HEPARANASE; HEPARANASE INHIBITOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; BETA GLUCURONIDASE; LUCIFERASE; PG 545; RECOMBINANT PROTEIN; SAPONIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; ENZYME ACTIVITY; FEMALE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; METASTASIS; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAJI CELL LINE; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR WEIGHT; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL PROLIFERATION; GLUCURONIDASE; HEK293 CELLS; HUMANS; LUCIFERASES; LYMPHOMA; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MOLECULAR WEIGHT; NEOPLASM METASTASIS; RECOMBINANT PROTEINS; SAPONINS; TUMOR BURDEN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955067497     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1519453113     Document Type: Article

References (50)

1. Parish CR, Freeman C, Hulett MD (2001) Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta 1471(3):M99-M108.
2. Vlodavsky I, Friedmann Y (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108(3):341-347.
3. Ilan N, Elkin M, Vlodavsky I (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38(12):2018-2039.
4. Vlodavsky I, Ilan N, Naggi A, Casu B (2007) Heparanase: Structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13(20):2057-2073.
5. Vreys V, David G (2007) Mammalian heparanase: What is the message? J Cell Mol Med 11(3):427-452.
6. Arvatz G, Barash U, Nativ O, Ilan N, Vlodavsky I (2010) Post-transcriptional regulation of heparanase gene expression by a 3′ AU-rich element. FASEB J 24(12): 4969-4976.
7. Cohen I, et al. (2006) Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 118(7):1609-1617.
8. Lerner I, et al. (2008) Function of heparanase in prostate tumorigenesis: Potential for therapy. Clin Cancer Res 14(3):668-676.
9. Casu B, Vlodavsky I, Sanderson RD (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36(3-4):195-203.
10. Dredge K, et al. (2010) The PG500 series: Novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs 28(3):276-283.
11. McKenzie EA (2007) Heparanase: A target for drug discovery in cancer and inflammation. Br J Pharmacol 151(1):1-14.
12. Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z (2006) Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 13(18):2101-2111.
13. Hammond E, Khurana A, Shridhar V, Dredge K (2014) The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol 4:195.
14. Kelly T, et al. (2003) High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 63(24):8749-8756.
15. Mahtouk K, et al. (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109(11):4914-4923.
16. Ritchie JP, et al. (2011) SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17(6):1382-1393.
17. Scott DW, Gascoyne RD (2014) The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 14(8):517-534.
18. Ansell SM (2015) Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clin Proc 90(8):1152-1163.
19. Dredge K, et al. (2011) PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer 104(4):635-642.
20. Shteper PJ, et al. (2003) Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 22(49):7737-7749.
21. Ferro V, et al. (2012) Discovery of PG545: A highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J Med Chem 55(8):3804-3813.
22. Levy-Adam F, et al. (2005) Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 280(21): 20457-20466.
23. Gingis-Velitski S, et al. (2004) Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem 279(42):44084-44092.
24. Fux L, et al. (2009) Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res 69(5):1758-1767.
25. Sanderson RD, Yang Y (2008) Syndecan-1: A dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 25(2):149-159.
26. Bar-Ner M, et al. (1987) Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 70(2): 551-557.
27. He X, et al. (2004) Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. Cancer Res 64(11):3928-3933.
28. Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA (2005) Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology (Carlton) 10(2):167-173.
29. Myler HA, Lipke EA, Rice EE, West JL (2006) Novel heparanase-inhibiting antibody reduces neointima formation. J Biochem 139(3):339-345.
30. Zetser A, et al. (2004) Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 117(Pt 11):2249-2258.
31. Spangler JB, et al. (2010) Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci USA 107(30):13252-13257.
32. Blonska M, Agarwal NK, Vega F (2015) Shaping of the tumor microenvironment: Stromal cells and vessels. Semin Cancer Biol 34:3-13.
33. Shain KH, Dalton WS, Tao J (2015) The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene 34(36):4673-4682.
34. Matzner Y, et al. (1985) Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. J Clin Invest 76(4):1306-1313.
35. Vlodavsky I, et al. (1992) Expression of heparanase by platelets and circulating cells of the immune system: Possible involvement in diapedesis and extravasation. Invasion Metastasis 12(2):112-127.
36. Hanahan D, Coussens LM (2012) Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309-322.
37. Mehta-Shah N, Younes A (2015) Novel targeted therapies in diffuse large B-cell lymphoma. Semin Hematol 52(2):126-137.
38. Ferro V (2013) Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses. Expert Opin Ther Targets 17(8):965-975.
39. Lindahl U, Kjellén L (2013) Pathophysiology of heparan sulphate: Many diseases, few drugs. J Intern Med 273(6):555-571.
40. Xu D, Esko JD (2014) Demystifying heparan sulfate-protein interactions. Annu Rev Biochem 83:129-157.
41. Elkin M, et al. (2001) Heparanase as mediator of angiogenesis: Mode of action. FASEB J 15(9):1661-1663.
42. Ebos JM (2015) Prodding the Beast: Assessing the Impact of Treatment-Induced Metastasis. Cancer Res 75(17):3427-3435.
43. Lerner I, et al. (2011) Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 121(5):1709-1721.
44. Ziolkowski AF, Popp SK, Freeman C, Parish CR, Simeonovic CJ (2012) Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes. J Clin Invest 122(1):132-141.
45. Gil N, et al. (2012) Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 61(1):208-216.
46. Gingis-Velitski S, Ishai-Michaeli R, Vlodavsky I, Ilan N (2007) Anti-heparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing. FASEB J 21(14):3986-3993.
47. Shafat I, et al. (2006) An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 341(4):958-963.
48. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V (1983) Lymphoma cellmediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: Relationship to tumor cell metastasis. Cancer Res 43(6):2704-2711.
49. Munoz R, et al. (2006) Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66(7):3386-3391.
50. Van Looy T, et al. (2015) Therapeutic efficacy assessment of CK6, a monoclonal KIT antibody, in a panel of gastrointestinal stromal tumor xenograft models. Transl Oncol 8(2):112-118.